LipoScience has secured $45 million in a just-completed initial public offering. The Raleigh, N.C.-based in vitro diagnostics company plans to use about $38.6 million in expected net proceeds from the offering in part to fund its research and development projects, including initiatives to increase its Vantera system's test menu.

Related Summaries